Skip Navigation



Japanese Journal of Clinical Oncology Advance Access published online on June 3, 2005
Japanese Journal of Clinical Oncology, doi:10.1093/jjco/hyi094
This Article
Right arrow FREE Full Text (PDF) Freely available
Right arrow All Versions of this Article:
35/6/342    most recent
hyi094v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Request Permissions
Google Scholar
Right arrow Articles by Shin, S. J.
Right arrow Articles by Song, H. S.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Shin, S. J.
Right arrow Articles by Song, H. S.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

© 2005 Foundation for Promotion of Cancer Research
Received February 10, 2005
Accepted April 27, 2005

Original Article

Expression of E-Cadherin and uPA and their Association with the Prognosis of Pancreatic Cancer

Sang Joon Shin 1, Kyeong Ok Kim 1, Min Kyoung Kim 1, Kyung Hee Lee 1*, Myung Soo Hyun 1, Keuk Jun Kim 2, Joon Hyuk Choi 2, and Hong Seok Song 3

1 Division of Oncology-Hematology, Department of Medicine, Yeungnam University College of Medicine, Daegu, Korea
2 Department of Pathology, Yeungnam University College of Medicine, Daegu, Korea
3 Keimyung University, Daegu, Korea

* To whom correspondence should be addressed.
Kyung Hee Lee, E-mail: lkhee{at}med.yu.ac.kr


  Abstract

Objective: E-cadherin (ECD) and urokinase plasminogen activator (uPA) have been noted as markers for tumor metastasis and prognosis in several tumors. We thus investigated the relationship between the expression of ECD and uPA and the clinicopathological characteristics in pancreatic cancer.

Methods: The expression of ECD and uPA was evaluated in pancreatic cancer tissues from 53 patients.

Results: Among 53 tumor tissues, those from 29 (54.7%) patients showed positive ECD expression and those from 22 (41.5%) patients showed positive expression of uPA. There were four subgroups of ECD/uPA expression: ECD-positive/uPA-negative, ECD-negative/uPA-negative, ECD-positive/uPA-positive and ECD-negative/uPA-positive. These patterns were found in 14 (26.4%), 11 (20.8%), nine (17%) and 19 (35.8%) patients, respectively. The tumor tissues with ECD-negative and uPA-positive expression were associated with larger tumor, distant metastasis and an increased clinical stage. There was a difference in the median survival time between the patients with ECD-positive/uPA-negative pancreatic tissues (median: 18.7 months) and the patients with ECD-negative/uPA-positive pancreatic tissues (median: 7.5 months, P < 0.05), and there was a statistically significant difference in survival curves between these two groups.

Conclusion: The combined analysis concerning uPA and E-cadherin expression may be a useful predictor of metastasis in pancreactic cancer.

Keywords: pancreatic neoplasms; E-cadherins; urokinase plasminogen activator.
Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
 Molecular Cancer TherapeuticsHome page
M. Zhu, V. M. Gokhale, L. Szabo, R. M. Munoz, H. Baek, S. Bashyam, L. H. Hurley, D. D. Von Hoff, and H. Han
Identification of a novel inhibitor of urokinase-type plasminogen activator
Mol. Cancer Ther., April 1, 2007; 6(4): 1348 - 1356.
[Abstract] [Full Text] [PDF]


Disclaimer: Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.